PDE4 inhibitors

Filaminast (WAY-PDA 641) was a drug candidate developed by Wyeth-Ayerst.

Rolipram is a selective phosphodiesterase-4 inhibitor discovered and developed by Schering AG as a potential antidepressant drug in the early 1990s.

Propentofylline (HWA 285) is a xanthine derivative with purported neuroprotective effects.

A phosphodiesterase type 4 inhibitor, commonly referred to as a PDE4 inhibitor, is a drug used to block the degradative action of phosphodiesterase 4 (PDE4) on cyclic adenosine monophosphate (cAMP).

Apremilast (brand name Otezla, by Celgene) is a drug for the treatment of certain types of psoriasis and psoriatic arthritis.

Etazolate (SQ-20,009, EHT-0202) is an anxiolytic drug which is a pyrazolopyridine derivative and has unique pharmacological properties.

Mesembrenone is an alkaloid constituent of Sceletium tortuosum (Kanna).

Luteolin is a flavone, a type of flavonoid.

Drotaverine (INN, also known as drotaverin) is an antispasmodic drug, used to enhance cervical dilation during childbirth.

Glaucine is an alkaloid found in several different plant species in the Papaveraceae family such as Glaucium flavum, Glaucium oxylobum and Corydalis yanhusuo, and in other plants like Croton lechleri in the family Euphorbiaceae.

Ibudilast (development codes: AV-411 or MN-166) is an anti-inflammatory drug used mainly in Japan, which acts as a phosphodiesterase inhibitor, inhibiting the PDE4 subtype to the greatest extent, but also showing significant inhibition of other PDE subtypes.

Piclamilast (RP 73401), is a selective PDE4 inhibitor.

RPL-554 (LS-193,855) is a drug candidate for respiratory diseases.

Roflumilast (trade names Daxas, Daliresp) is a drug that acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4).

Mesembrine is an alkaloid present in Sceletium tortuosum (kanna).

Pentoxifylline (INN, BAN, USAN) or oxpentifylline (AAN) is a is a xanthine derivative used as a drug to treat muscle pain in people with peripheral artery disease.

Cilomilast (INN, codenamed SB-207,499, proposed trade name Ariflo) is a drug which was developed for the treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD).

Crisaborole (INN, USAN, codenamed AN2728) is a non-steroidal, topical drug candidate that as of 2015 was under development by Anacor Pharmaceuticals for the topical treatment of psoriasis and atopic dermatitis (atopic eczema).